Breast Cancer Coverage from Every Angle
Advertisement
Advertisement

Managing Breast Cancer in Older Adults: An Updated International Policy Review

By: Cordi Craig, MS
Posted: Monday, August 2, 2021

Despite the increasing prevalence of breast cancer among older adults, cancer management remains challenging because of the heterogeneity of the disease and insufficient data representative of the geriatric population. In a joint report from the European Society of Breast Cancer Specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG), a panel of experts updated the 2012 evidence-based recommendations for breast cancer management among older populations. The Policy Review was published in The Lancet Oncology.

“The management of breast cancer in older adults should consider the intrinsic heterogeneity of this population and involve routine use of geriatric assessments and close interaction with members of the multidisciplinary team,” Etienne G.C. Brain, MD, of Institut Curie, Paris, and colleagues concluded.

In 2007, a multidisciplinary task force included specialists in medical and radiation oncology, surgery, geriatrics, radiology, epidemiology, and patient advocates; it was created to prepare guidelines for breast cancer management among older adults. Updated guidelines were subsequently published in 2012. New evidence has become available since 2012, and a Policy Review of the most up-to-date recommendations for breast cancer management was prepared based on available evidence and the consensus of a panel of experts.

In clinical decision-making, the Policy Report concluded that the management of breast cancer in older adults should more seriously consider the heterogeneity of the patient population. The guidelines recommend the routine use of geriatric assessments and close communication with a multidisciplinary team. Evidence generated in younger or more fit individuals is less applicable, according to the Policy Report. Thus clinicians and patients should consider various factors, including patient preferences, life expectancy, predicted survival benefits, and the effect of toxicity on quality of life.

Disclosure: For full disclosures of the study authors, visit thelancet.com.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.